Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel-Group, Multicenter Study to Examine the Safety, Tolerability, and Body Weight Effect of Subcutaneous Pramlintide Alone and in Combination With the Oral Antiobesity Agents Sibutramine or Phentermine in Overweight and Obese Subjects

NCT00402077 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00402077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00402077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel-Group, Multicenter Study to Examine the Safety, Tolerability, and Body Weight Effect of Subcutaneous Pramlintide Alone and in Combination With the Oral Antiobesity Agents Sibutramine or Phentermine in Overweight and Obese Subjects
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2006
Completion date
August 31, 2007
Enrollment
258 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight